Abstract 67P
Background
Inflammation is a key factor in the pathogenesis of sarcopenia, a negative prognostic factor in cancer. Higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall survival (OS) across multiple tumor types and can serve as cost-effective surrogate biomarker of a preexisting inflammatory status. We aimed to assess the combined prognostic value of sarcopenia and NLR in IO-treated pt.
Methods
Retrospective analysis of pt with metastatic solid tumors treated with IO within the MP and the ME (off-label/expanded access use) programs at the Catalan Institute of Oncology between Jan’11-Dec’19. Included pt had clinic-analytical data and computed tomography scans performed as standard practice within a month before first IO dose. To analyze sarcopenia, skeletal mass index (SMI) was calculated using Slice-O-Matic software at L3 landmark and sarcopenia was dichotomized according to the median baseline SMI (high versus low). High NLR (>=3) versus low NLR (<3) was calculated in baseline IO-blood test. Kaplan-Meier was used to estimate median OS and log-rank test was used to compare survival curves.
Results
We included 90 pt: the majority were male (66%), <75 years (76%), ECOG <2 (89%), <2 sites of metastases (61%) and had received <3 lines of treatment (93%). Most common tumors were lung (37%) genitourinary (29%), skin (27%) and others (8%, including gynecological, gastrointestinal, sarcomas and SCCHN). Sarcopenia was detected in half of pt of whom 67% had high NLR. OS was 23.5 months (m) in high SMI/low NLR, 12.3m in high SMI/high NLR, 11.8m in low SMI/low NLR and 3 m in low SMI/high NLR groups (p=0.0003). Noteworthy, OS rate at 12 m was 75% (CI 95%; 60-94) in high SMI/low NLR group, whilst in low SMI/high NLR group was 27% (CI 95%; 15-48) (p=0.0001).
Conclusions
The combination of both widely accessible prognostic biomarkers may help in MP and ME programs decision-making, by identifying the subgroup of low SMI/high NLR patients with worse prognosis to better select candidates. Strategies for reducing systemic inflammation and improving skeletal muscle mass are warranted to increase benefits of IO.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract